GVHD the first step, page-3

As usual @dachopper a great overview.
Even the Great" Bell Potter" has MSB on there radar:

Mesoblast is a global leader of the development of stem cell technology for the treatment of inflammatory disease including graft versus host, chronic lower back pain, crohn’sand colitis to mention a few.
The lead product is remestemcel-L for treatment of acute steroid refractory graft versus host disease in paediatric patients following bone marrow transplant for the treatment of cancer.
The company is now on the cusp of resubmitting its biological license application (BLA) for this product following years of work in the clinic.
The corner stones of the resubmitted BLA include new long term survival data over 2 and 4 years together with potency assays for each batch of product.
The BLA is expected to be submitted in January 2023 with a potential approval by mid CY2023.

Closing cash at 30 September was US$85.5m.

I guess with BP having a current valuation reported at $1.65 they believe things are about to happen, so for all us long time holders and beleivers such as ecoool2, stanjupiter, LeftYahoo, Stockrock, The Yankee, Wombat777, Phaedrus, LearningEachDay, dplane, and of course ddwn who have always contributed entertaining positive posts.

I keep going back to what Itescu quoted: “The FDA has previously said they don’t want to have unregistered use of stem cells. They want to make sure that when they approve the first product, they are not opening a Pandora’s box, Itescu says."

So, anything new takes time and the FDA spelt it out what they wanted from the Company & I am sure Silviu will provide it when ready as you have pointed out.

ST